|
|
| | XL-765,SAR245409 Basic information |
| Product Name: | XL-765,SAR245409 | | Synonyms: | XL-765,SAR245409;XL765;N-[2-[(3,5-Dimethoxyphenyl)amino]quinoxalin-3-yl]-4-[(4-methyl-3-methoxyphenyl)carbonyl]aminophenylsulfonamide;N-(4-(N-(3-((3,5-DiMethoxyphenyl)aMino)quinoxalin-2-yl)sulfaMoyl)phenyl)-3-Methoxy-4-MethylbenzaMide;SAR245409;XL765(Voxtalisib);CS-432;XL-765,SAR245409 USP/EP/BP | | CAS: | 1123889-87-1 | | MF: | C31H29N5O6S | | MW: | 599.65686 | | EINECS: | | | Product Categories: | | | Mol File: | 1123889-87-1.mol |  |
| | XL-765,SAR245409 Chemical Properties |
| density | 1.387 | | solubility | Soluble in DMSO | | form | Powder |
| | XL-765,SAR245409 Usage And Synthesis |
| Uses | XL765 is a low-molecular mass PI3K inhibitor that also inhibits DNA-PK and mTOR. | | Definition | ChEBI: XL765 is a sulfonamide obtained by formal condensation of the sulfonic acid group of 4-[(3-methoxy-4-methylbenzoyl)amino]benzenesulfonic acid with the primary aromatic amino group of N-(3,5-dimethoxyphenyl)quinoxaline-2,3-diamine. A dual PI3K/mTOR inhibitor used in cancer treatment. It has a role as an EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor, an antineoplastic agent and a mTOR inhibitor. It is a sulfonamide, a quinoxaline derivative, an aromatic amine, a member of benzamides and an aromatic ether. | | target | p110α |
| | XL-765,SAR245409 Preparation Products And Raw materials |
|